tetano
Editor, Senior Moderator
J Cyst Fibros
. 2020 Nov 4;S1569-1993(20)30877-8.
doi: 10.1016/j.jcf.2020.10.003. Online ahead of print.
The global impact of SARS-CoV-2 in 181 people with cystic fibrosis
Elliot McClenaghan[SUP] 1 [/SUP], Rebecca Cosgriff[SUP] 2 [/SUP], Keith Brownlee[SUP] 2 [/SUP], Susannah Ahern[SUP] 3 [/SUP], Pierre-R?gis Burgel[SUP] 4 [/SUP], Catherine A Byrnes[SUP] 5 [/SUP], Carla Colombo[SUP] 6 [/SUP], Harriet Corvol[SUP] 7 [/SUP], Stephanie Y Cheng[SUP] 8 [/SUP], G?raldine Daneau[SUP] 9 [/SUP], Alexander Elbert[SUP] 10 [/SUP], Albert Faro[SUP] 10 [/SUP], Christopher H Goss[SUP] 11 [/SUP], Vincent Gulmans[SUP] 12 [/SUP], Hector Gutierrez[SUP] 13 [/SUP], Isabelle de Monestrol[SUP] 14 [/SUP], Andreas Jung[SUP] 15 [/SUP], Lutz N?hrlich Justus[SUP] 16 [/SUP], Nataliya Kashirskaya[SUP] 17 [/SUP], Bruce C Marshall[SUP] 10 [/SUP], Edward McKone[SUP] 18 [/SUP], Peter G Middleton[SUP] 19 [/SUP], Pedro Mondejar-Lopez[SUP] 20 [/SUP], M Dolores Pastor-Vivero[SUP] 21 [/SUP], Rita Padoan[SUP] 22 [/SUP], Samar Rizvi[SUP] 10 [/SUP], Rasa Ruseckaite[SUP] 3 [/SUP], Marco Salvatore[SUP] 23 [/SUP], Anne Stephenson[SUP] 24 [/SUP], Luiz Vicente R da Silva Filho[SUP] 25 [/SUP], Joel Melo[SUP] 26 [/SUP], Marco Zampoli[SUP] 27 [/SUP], Siobh?n B Carr[SUP] 28 [/SUP]
Affiliations
Abstract
With the growing SARS-CoV-2 pandemic, we need to better understand its impact in specific patient groups like those with Cystic Fibrosis (CF). We report on 181 people with CF (32 post-transplant) from 19 countries diagnosed with SARS-CoV-2 prior to 13 June 2020. Infection with SARS-CoV-2 appears to exhibit a similar spectrum of outcomes to that seen in the general population, with 11 people admitted to intensive care (7 post-transplant), and 7 deaths (3 post-transplant). A more severe clinical course may be associated with older age, CF-related diabetes, lower lung function in the year prior to infection, and having received an organ transplant. Whilst outcomes in this large cohort are better than initially feared overall, possibly due to a protective effect of the relatively younger age of the CF population compared to other chronic conditions, SARS-CoV-2 is not a benign disease for all people in this patient group.
Keywords: COVID-19; Coronavirus; Cystic fibrosis; SARS-CoV-2; Transplant.
. 2020 Nov 4;S1569-1993(20)30877-8.
doi: 10.1016/j.jcf.2020.10.003. Online ahead of print.
The global impact of SARS-CoV-2 in 181 people with cystic fibrosis
Elliot McClenaghan[SUP] 1 [/SUP], Rebecca Cosgriff[SUP] 2 [/SUP], Keith Brownlee[SUP] 2 [/SUP], Susannah Ahern[SUP] 3 [/SUP], Pierre-R?gis Burgel[SUP] 4 [/SUP], Catherine A Byrnes[SUP] 5 [/SUP], Carla Colombo[SUP] 6 [/SUP], Harriet Corvol[SUP] 7 [/SUP], Stephanie Y Cheng[SUP] 8 [/SUP], G?raldine Daneau[SUP] 9 [/SUP], Alexander Elbert[SUP] 10 [/SUP], Albert Faro[SUP] 10 [/SUP], Christopher H Goss[SUP] 11 [/SUP], Vincent Gulmans[SUP] 12 [/SUP], Hector Gutierrez[SUP] 13 [/SUP], Isabelle de Monestrol[SUP] 14 [/SUP], Andreas Jung[SUP] 15 [/SUP], Lutz N?hrlich Justus[SUP] 16 [/SUP], Nataliya Kashirskaya[SUP] 17 [/SUP], Bruce C Marshall[SUP] 10 [/SUP], Edward McKone[SUP] 18 [/SUP], Peter G Middleton[SUP] 19 [/SUP], Pedro Mondejar-Lopez[SUP] 20 [/SUP], M Dolores Pastor-Vivero[SUP] 21 [/SUP], Rita Padoan[SUP] 22 [/SUP], Samar Rizvi[SUP] 10 [/SUP], Rasa Ruseckaite[SUP] 3 [/SUP], Marco Salvatore[SUP] 23 [/SUP], Anne Stephenson[SUP] 24 [/SUP], Luiz Vicente R da Silva Filho[SUP] 25 [/SUP], Joel Melo[SUP] 26 [/SUP], Marco Zampoli[SUP] 27 [/SUP], Siobh?n B Carr[SUP] 28 [/SUP]
Affiliations
- PMID: 33183965
- DOI: 10.1016/j.jcf.2020.10.003
Abstract
With the growing SARS-CoV-2 pandemic, we need to better understand its impact in specific patient groups like those with Cystic Fibrosis (CF). We report on 181 people with CF (32 post-transplant) from 19 countries diagnosed with SARS-CoV-2 prior to 13 June 2020. Infection with SARS-CoV-2 appears to exhibit a similar spectrum of outcomes to that seen in the general population, with 11 people admitted to intensive care (7 post-transplant), and 7 deaths (3 post-transplant). A more severe clinical course may be associated with older age, CF-related diabetes, lower lung function in the year prior to infection, and having received an organ transplant. Whilst outcomes in this large cohort are better than initially feared overall, possibly due to a protective effect of the relatively younger age of the CF population compared to other chronic conditions, SARS-CoV-2 is not a benign disease for all people in this patient group.
Keywords: COVID-19; Coronavirus; Cystic fibrosis; SARS-CoV-2; Transplant.